1. GLP-1 agonists in type 1 diabetes.
- Author
-
Pettus J, Hirsch I, and Edelman S
- Subjects
- Animals, Biomarkers blood, Blood Glucose metabolism, C-Peptide blood, Clinical Trials as Topic, Diabetes Mellitus, Type 1 metabolism, Diabetes Mellitus, Type 1 pathology, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 pathology, Exenatide, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide 1 metabolism, Glucagon-Like Peptide 1 therapeutic use, Glycated Hemoglobin metabolism, Humans, Insulin-Secreting Cells metabolism, Insulin-Secreting Cells pathology, Liraglutide, Peptides therapeutic use, Venoms therapeutic use, Diabetes Mellitus, Type 1 drug therapy, Glucagon-Like Peptide 1 agonists, Hypoglycemic Agents therapeutic use, Insulin-Secreting Cells drug effects
- Abstract
Despite years of research in the field of type 1 diabetes, patients with the disease remain without a therapeutic agent that can alter the underlying immune response in a clinically beneficial way. Glucagon-like peptide 1 agonist therapies have shown some promising effects in terms of positively affecting overall beta cell health and increasing beta cell mass, primarily in mouse models. The three agents of this class currently available for patients with type 2 diabetes have shown beneficial clinical effects on glucose control in this patient population. The purpose of this article is to review the preclinical and clinical data of these agents to date with a focus on the potential immunological and clinical benefits these drugs may have on patients with type 1 diabetes., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF